RxDoctor Payments DataLook up a doctor →

Mohammad Ansari, MD

Interventional Cardiology · Lubbock, TXNPI 1073762084

Payments from drug & device makers

$960,651in general payments, 2019–2025

Across 1,071 payments — averaging $896.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$373K
  • Inari Medical, Inc.$130K
  • Abbott$114K
  • Terumo Medical Corporation$78K
  • Catheter Precision, Inc. FKA Ra Medical Systems, Inc.$77K
  • Bard Peripheral Vascular, Inc.$26K
  • plus $164K from 35 others

What the payments were for

  • Consulting fees$123,83354%
  • Speaking & faculty fees$47,14521%
  • Grants$1350%
  • Travel & lodging$37,50816%
  • Food & beverage$18,7918%
  • Education$900%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$960,651 in reported general payments places this provider in the 95th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$73,265
Medicare patients
313
Services billed
875

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban143$120,531
XareltoRivaroxaban121$89,123
EntrestoSacubitril/Valsartan105$83,985
JardianceEmpagliflozin48$36,808
FarxigaDapagliflozin Propanediol32$25,836
BrilintaTicagrelor21$11,775
Rosuvastatin Calcium336$3,999
Bumetanide24$2,733
Ranolazine ErRanolazine26$2,662
Metoprolol Succinate166$2,639
Potassium Chloride90$2,042
Sildenafil Citrate12$1,763
Atorvastatin Calcium291$1,757
Carvedilol209$1,259
Prasugrel Hcl24$1,226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$219$89,123121 claims
NovartisEntresto$1,414$83,985105 claims
AstraZenecaFarxiga, Brilinta$193$37,61153 claims
Boehringer IngelheimJardiance$14$36,80848 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Lubbock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →